Potential role of oral thiazolidinedione therapy in preserving β-cell function in type 2 diabetes mellitus

Drugs

Volumn 65, Issue 1, 2005, Pages 1-13

  Walter, Helmut ^a   Lübben, Georg ^b  

^a KLINIKUM NÜRNBERG   (Germany)

^b Takeda Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLOID; FATTY ACID; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ANIMAL CELL; APOPTOSIS; CELL SURVIVAL; CLINICAL TRIAL; DISEASE EXACERBATION; FEMALE; HAMSTER; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; INNER CELL MASS; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; MOUSE; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSCILLATION; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; RAT; REVIEW; RISK REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; ISLETS OF LANGERHANS; THIAZOLIDINEDIONES;

ANIMALIA; CRICETINAE; RATTUS NORVEGICUS;

EID: 12444281820     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565010-00001     Document Type: Review

References (98)

1. UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352 (9131): 837-53
2. Buchanan T, Xiang A, Peters R, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51 (9): 2796-803
3. Dubois M, Pattou F, Kerr-Conte J, et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000; 43 (9): 1165-9
4. Kawai T, Hirose H, Seto Y, et al. Troglitazone ameliorates lipotoxicity in the beta cell line INS-1 expressing PPAR gamma. Diabetes Res Clin Pract 2002; 56 (2): 83-92
5. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia 1999; 42 (9): 1033-49
6. Matthews D, Cull C, Stratton I, et al. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 1998; 15: 297-303
7. Östgren C, Lindblad U, Ranstam J, et al. Glycaemic control, disease duration and beta-cell function in patients with type 2 diabetes in a Swedish community: Skaraborg Hypertension and Diabetes Project. Diabet Med 2002; 19 (2): 125-9
8. Kahn S. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000; 108 Suppl. 6A: 2S-8S
9. Buchanan T. Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin Ther 2003; 25 Suppl. B: B32-46
10. Bonner-Weir S. Beta-cell turnover: its assessment and implications. Diabetes 2001; 50 Suppl. 1: S20-4
11. Butler A, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-10
12. Shafrir E, Ben-Sasson R, Ziv E, et al. Insulin resistance, beta-cell survival, and apoptosis in type 2 diabetes: animal models and human implications. Diabetes Rev 1999; 7: 144-53
13. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992; 13: 415-31
14. Robertson R, Olson L, Zhang H. Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes 1994; 43: 1085-9
15. Leahy J, Bonner-Weir S, Weir G. Beta-cell dysfunction induced by chronic hyperglycemia: current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992; 15: 442-55
16. Bonner-Weir S, Trent D, Weir G. Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 1983; 71: 1544-53
17. Finegood D, Topp B. Beta-cell deterioration: prospects for reversal or prevention. Diabetes Obes Metab 2001; 3 Suppl. 1: S20-7
18. Levy J, Atkinson A, Bell P, et al. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998; 15 (4): 290-6
19. Diani A, Sawaka G, Wyse B, et al. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 2004; 286(1): E116-22
20. McGarry J, Dobbins R. Fatty acid, lipotoxicity and insulin secretion. Diabetologia 1999; 42: 128-38
21. Zhou Y, Grill V. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 1994; 93 (2): 870-6
22. Zhou Y, Grill V. Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 1995; 80 (5): 1584-90
23. Lee Y, Hirose H, Ohneda M, et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A 1994; 91 (23): 10878-82
24. Lee Y, Hirose H, Zhou YT, et al. Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes 1997; 46 (3): 408-13
25. Shimabukuro M, Zhou Y, Levi M, et al. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 1998; 95 (5): 2498-502
26. Lupi R, Dotta F, Marselli L, et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 2002; 51 (5): 1437-42
27. Kashyap S, Belfort R, Gastaldelli A, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003; 52: 2461-74
28. Stein D, Stevenson B, Chester M. The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J Clin Invest 1997; 100: 398-403
29. Kawai T, Hirose H, Seto Y, et al. Chronic effects of different fatty acids and leptin in INS-1 cells. Diabetes Res Clin Pract 2001; 51: 1-8
30. Komatsu M, Sharp G. Palmitate and myristate selectively mimic the effect of glucose in augmenting insulin release in the absence of extracellular Ca2+. Diabetes 1998; 47: 352-7
31. Del Prato S, Wishner W, Gromada J, et al. Beta-cell mass plasticity in type 2 diabetes. Diabetes Obes Metab 2004; 6 (5): 319-31
32. Hayden M, Tyagi S. Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. JOP 2002; 3 (4): 86-108
33. Ward W, LaCava E, Paquette T, et al. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987; 30 (9): 698-702
34. Haffner S, Gonzalez C, Mykkanen L, et al. Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion to NIDDM: the Mexico City Diabetes Study. Diabetologia 1997; 40 (7): 830-7
35. Mykkanen L, Zaccaro D, Hales C, et al. The relation of proinsulin and insulin to insulin sensitivity and acute insulin response in subjects with newly diagnosed type II diabetes: the Insulin Resistance Atherosclerosis Study. Diabetologia 1999; 42: 1060-6
36. Burant C. Role of PPARs in preserving the beta-cell [abstract]. Second International Symposium on PPARs: from basic science to clinical applications; 2003 Mar 19-22; Florence
37. Shimabukuro M, Zhou Y, Lee Y, et al. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 1998; 273 (6): 3547-50
38. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-14
39. Hotamisligil G, Murray D, Choy L, et al. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 1994; 91: 4854-8
40. Hotamisligil G, Shargill N, Spiegelman B. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-90
41. Hotamisligil G, Peraldi P, Budavari A, et al. 1RS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-8
42. Uysal K, Wiesbrock S, Marino M, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-4
43. Peraldi P, Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem 1998; 182: 169-75
44. Kwon G, Xu G, Marshall CA, et al. Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta12,14-prostaglandin J2 and aminoguanidine: a role for peroxisome proliferator-activated receptor gamma activation and inos expression. J Biol Chem 1999; 274 (26): 18702-8
45. Shimabukuro M, Koyama K, Chen G, et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A 1997; 94 (9): 4637-41
46. Finegood D, McArthur M, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50 (5): 1021-9
47. Kawasaki F, Matsuda M, Inoue H, et al. Prevention of pancreatic beta cell damage by pharmacological interventions in db/db mice: implications for glucolipotoxicity mechanism. Diabetologia 2002; 45 Suppl. 2: A146-7
48. Lupi R, Del Guerra S, Fierabracci V, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002; 51 Suppl. 1: S134-7
49. Lupi R, Del Guerra S, Marselli L, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 2004; 286 (4): E560-7
50. Marselli L, Bambini M, Lupi R, et al. Rosiglitazone partially prevents free-fatty acid-induced cytotoxicity in human pancreatic islet cells [abstract no. 494], Diabetologia 2002; 45 Suppl. 2: A161,
51. Masuda K, Okamoto Y, Tsuura Y, et al. Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 1995; 38 (1): 24-30
52. Prigeon R, Kahn S, Porte Jr D. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 1998; 83 (3): 819-23
53. Porter L, Freed M, Jones N, et al. Rosiglitazone reduces proinsulin/insulin ratio and improves beta-cell function in type 2 diabetes [abstract no. 737]. Diabetologia 2000; 43 Suppl. 1: A192
54. Kubo K. Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. Endocr J 2002; 49 (3): 323-8
55. Koro C, Fu Q, Dirani R, et al. Beneficial effects of thiazolidinediones on myocardial infarction risk in patients with type 2 diabetes [abstract]. American Diabetes Association, 64th Scientific Sessions; 2004 Jun 4-8; Florida
56. Nakamichi Y, Kikuta T, Ito E, et al. PPAR-gamma overexpression suppresses glucose-induced proinsulin biosynthesis and insulin release synergistically with pioglitazone in MIN6 cells. Biochem Biophys Res Commun 2003; 306: 832-6
57. Jia D, Otsuki M. Troglitazone stimulates pancreatic growth in normal rats. Pancreas 2002; 24 (3): 303-12
58. Tanwani L, Lohano V, Stagner J, et al. Troglitazone prolongs the functional longevity of transplanted islets [abstract]. Diabetes 2001; 50 Suppl. 2: A412
59. Fujiwara T, Wada M, Fukuda K, et al. Characterization of CS-045, a new oral antidiabetic agent: II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 1991; 40 (11): 1213-8
60. Ishida H, Takizawa M, Ozawa S, et al. Pioglitazone improves insulin secretory capacity and prevents the loss of beta cell mass in obese diabetic db/db mice: possible protection of beta cells from oxidative stress. Metabolism 2004; 53 (4): 488-94
61. Dachicourt N, Bailbe D, Gangnerau M, et al. Effect of gliclazide treatment on insulin secretion and beta-cell mass in non-insulin dependent diabetic Goto-Kakisaki rats. Eur J Pharmacol 1998; 361 (2-3): 243-51
62. Shen Z, Hull R, Kodama K, et al. Long-term rosiglitazone and metformin treatment reduce the severity of islet amyloid but do not prevent its formation [abstract]. Diabetes 2003; 52 Suppl. 1: A338
63. Kahn C, Chen L, Cohen S. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 2000; 106 (11): 1305-7
64. Wallace T, Matthews D. Coefficient of failure: a methodology for examining longitudinal beta-cell function in type 2 diabetes. Diabet Med 2002; 19 (6): 465-9
65. 1c in drug-naive patients treated with pioglitazone, metformin or gliclazide monotherapy [abstract no. 586-P]. Diabetes 2003; 52 Suppl. 1: 137
66. Moules I, Edwards G, Mariz S, et al. Two-year efficacy of the addition of pioglitazone to sulfonylurea therapy in patients with T2DM [abstract]. American Diabetes Association, 64th Scientific Sessions; 2004 Jun 4-8; Florida
67. Urquhart R, Mariz S, Edwards G, et al. Two-year effects of pioglitazone addition to sulfonylurea or metformin therapy on fasting serum insulin in patients with type 2 diabetes [abstract]. American Diabetes Association, 64th Scientific Sessions; 2004 Jun 4-8; Florida
68. Urquhart R, Tan M, Mariz S, et al. Long-term (2-year) effects on HOMA-%S, an estimate of insulin sensitivity, of pioglitazone, gliclazide and metformin as add-on therapies in patients with T2DM [abstract]. American Diabetes Association, 64th Scientific Sessions; 2004 Jun 4-8; Florida
69. Edwards G, Urquhart R, Moules I, et al. Two-year efficacy of pioglitazone versus gliclazide addition to metformin therapy in T2DM [abstract]. American Diabetes Association, 64th Scientific Sessions; 2004 Jun 4-8; Florida
70. Tan M, Johns D, Urquhart R, et al. Pioglitazone (PIO) is superior to gliclazide (GLIC) in sustaining glycemic control in patients with type 2 diabetes (T2D) [abstract]. American Diabetes Association, 64th Scientific Sessions; 2004 Jun 4-8; Florida
71. Gastaldelli A, Mari A, Miyazaki Y, et al. Thiazolidinediones improve beta-cell function in type 2 diabetic patients [abstract]. American Diabetes Association, 64th Scientific Sessions; 2004 Jun 4-8; Florida
72. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000; 23 (11): 1605-11
73. Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12 (5): 413-23
74. Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003; 25 (4): 1074-95
75. Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88 (4): 1637-45
76. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000; 22 (12): 1395-409
77. Patel J, Anderson R, Rappaport E. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999; 1 (3): 165-72
78. Nolan JJ, Jones NP, Patwardhan R, et al. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 2000; 17 (4): 287-94
79. Lebovitz H, Dole J, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86 (1): 280-8
80. Raskin P, Rappaport E, Cole S, et al. Rosiglitazone short-term monotherapy lowers fasting post-prandial glucose in patients with type 2 diabetes. Diabetologia 2000; 43 (3): 278-84
81. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283 (13): 1695-702
82. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997; 46 (3): 433-9
83. Yale JF, Valiquett TR, Ghazzi MN, et al. The effect of a thiazolidinedione drug, trogtitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin: a multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134 (9 Pt 1): 737-45
84. Juhl CB, Hollingdal M, Porksen N, et al. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab 2003; 88 (8): 3794-800
85. Li J, Tian H, Ren Y, et al. Effect of pioglitazone on first phase insulin secretion in type 2 diabetes mellitus and impaired glucose intolerance [abstract no. 1212-P]. Diabetes 2003; 52 Suppl. 1: A281
86. Ovalle F, Bell D. Effect of rosiglitazone vs insulin on the pancreatic beta cell function of subjects with type 2 diabetes mellitus [abstract no. 556-P]. Diabetes 2003; 52 Suppl. 1: A130
87. Cavaghan M, Ehrmann D, Byrne M, et al. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997; 100 (3): 530-7
88. Ovalle F, Bell D. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4 (1): 56-9
89. Pfützner A, Langenfeld M, Butzer R, et al. Influence of pioglitazone on insulin resistance, β-cell secretion, and cardiovascular risk markers in comparison to glimepiride in patients with type 2 diabetes [abstract]. American Diabetes Association, 64th Scientific Sessions; 2004 Jun 4-8; Florida
90. Rasouli N, Miles L, Raue U, et al. Pioglitazone (PIO) but not metformin (MET) improves lipotoxicity, insulin sensitivity, and β cell function in subjects with impaired glucose tolerance (IGT) [abstract]. American Diabetes Association, 64th Scientific Sessions; 2004 Jun 4-8; Florida
91. Vinik A, Yu D, Strow L, et al. Long-term effect of rosiglitazone on pancreatic β-cell function and insulin resistance in older type 2 diabetes mellitus (T2DM) patients treated with sulfonylurea [abstract]. American Diabetes Association, 64th Scientific Sessions; 2004 Jun 4-8; Florida
92. Wallace T, Levy J, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004; 21 (6): 568-76
93. Albertini JP, Chen H, Mather R, et al. Markers of endothelial dysfunction and insulin resistance: beneficial effects of rosiglitazone in type 2 diabetes [abstract]. American Diabetes Association, 64th Scientific Sessions; 2004 Jun 4-8; Florida
94. Raji A, Gerhard-Herman M, Knauft W, et al. Effect of pioglitazone on insulin sensitivity, vascular reactivity and cardiovascular risk factors in Asian Indians [abstract]. American Diabetes Association, 64th Scientific Sessions; 2004 Jun 4-8; Florida
95. Salameh B, Lee S, Petrofsky J, et al. Rapid and significant improvements in resting forearm blood flow and post-occlusive endothelial dependent forearm flow with rosiglitazone in type 2 diabetes [abstract]. American Diabetes Association, 64th Scientific Sessions; 2004 Jun 4-8; Florida
96. Weissman P, Goldstein J, Campbell J, et al. Rosiglitazone plus metformin combination effects on CV risk markers suggest potential CV benefits in type 2 diabetic patients [abstract]. American Diabetes Association, 64th Scientific Sessions; 2004 Jun 4-8; Florida
97. Bahia L, Godoy-Matos A, Bottino D, et al. Rosiglitazone improves cardiovascular risk factors and insulin resistance in insulin-resistant nondiabetic Brazilian subjects [abstract]. American Diabetes Association, 64th Scientific Sessions; 2004 Jun 4-8; Florida
98. Charbonnel B, Dormandy J, Erdmann E, et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients: PROactive Study Group. Diabetes Care 2004; 27 (7): 1647-53